Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (931)	11/8/1997 11:05:00 PM
From: D.Right	Read Replies (3) \| Respond to of 2173

Dear Henry: You missed the point. Under normal conditions (non-diabetic condition), PPAR gamma is not supposed to be activated, it is not whether Resulin is an analog of non-peptide hormone or not. On the other hand, amylin does exist in everyone's body (only missing in diabetic patients), so pramlintide's receptor (still not very well defined) should be activated (by amylin in normal or pramlintide in patients). The most important information here is a paper published by AMLN's scientists, which showed the normal level of amylin and the lack of it in diabetic patients. You can check that out on AMLN's home page. I would be more than happy to help if you can not find it. Also, if you have information showing that PPAR gamma should be activated under normal condition but missing in diabetic patients, please share it here. Of course, many great drugs are "add on" drugs like the pair from Amgen. The only problem is when you use "add on" drugs on a long term bases (like for diabetes), the potential side effects are unknown, which is what happened to Resulin last week. Good luck